Talquetamab
Active substance | Talquetamab | ||
Holder | Janssen-Cilag NV | ||
Status | Running | ||
Indication | As monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least 3 prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody and have demonstrated disease progression on the last therapy |
Active substance Circulars published in 202314 September 2023 - Circulaire n° 648 - Omzendbrief nr. 648 Interpretation of the royal decree of 11 June 2015: regulating products containing one or more tetrahydrocannabinols for raw materials for magistral preparations. Ozempic: modification of the recommendations for medical doctors (specialists) and (hospital) pharmacists due to limited availabilityThere is limited availability of the medicine Ozempic (semaglutide-based solution for subcutaneous injection) due to an acute increase in demand. This limited availability will certainly last until early 2024. Rybelsus (semaglutide-based tablets) is also unavailable. The experts from the FAMHP's Unavailability Task Force adapt the recommendations.
Fighting antimicrobial resistance: new antimicrobial medicinal products marketed in BelgiumIn the fight against antimicrobial resistance (AMR), it is important to improve the diversity of therapeutic treatments to enable medical doctors to make the most appropriate choice. A new dosage for children has recently been launched on the Belgian market for a pheneticillin-based antibiotic and two antivirals, one composed of bictegravir, emtricitabine and tenofovir and the other composed of dolutegravir, abacavir and lamivudine.
Unavailability of high-dose methotrexate: situation normalised, recommendations liftedThe supply of high-dose methotrexate, used in oncology, was temporarily limited worldwide. The situation has since returned to normal, allowing the task force's recommendations to be lifted.
Hugues Malonne is the FAMHP's new Chief Executive OfficerHugues Malonne appointed new FAMHP Chief Executive Officer by the federal government
Camzyos
|